Condensed Consolidated Statement of Cash Flows $ in Thousands	6 Months Ended
	Sep. 30, 2016 USD ($)
Cash flows from operating activities:
Net loss	$ (53,683)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	4,771
Depreciation	1
Purchase of in-process research and development expense	13,117
Changes in the fair value of the warrant liability	29,817
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(38)
Due to Roivant Sciences Ltd. and Roivant Sciences, Inc.	4,014
Other assets	(100)
Accrued expenses and accounts payable	1,413
Income tax payable	1
Net cash used in operating activities	(687)
Cash flows from investing activities:
Net cash used in investing activities	0
Cash flows from financing activities:
Cash capital contribution from Roivant Sciences Ltd.	831
Deferred initial public offering costs	(71)
Net cash provided by financing activities	760
Net change in cash	73
Cash—beginning of period	0
Cash—end of period	73
Non-cash financing activities:
Deferred initial public offering costs, unpaid	1,603
Purchase of in-process research and development	13,117
Supplemental disclosure of cash paid:
Taxes	$ 10